VANCOUVER, Feb. 24 /CNW/ - CRH Medical Corporation announced today that
through its Partnership Program, the CRH O'Regan Hemorrhoid banding technology
has been adopted by more than 90% of the gastroenterologist practice groups
trained by the Company since June 2008. The Company believes this provides
clear evidence of not only a strong medical need, but also confirmation of the
consistency of its training methodology. The sharing of knowledge and
experience from our CRH Centers for Colorectal Health to individual physicians
through our Partnership Program has gone smoothly, with continued high levels
of safety and successful treatment outcomes.
The Company has now trained over two hundred physicians representing over
40 practice groups in 30 markets across the United States. The diagnosis of
hemorrhoids requiring treatment during colonoscopy is very common. The CRH
technology provides physicians with an effective modality to treat
hemorrhoidal disease. It is clear by the significant adoption rate amongst
physicians that the treatment of hemorrhoids is a natural extension of their
practice. With over 8,000 gastroenterologists in the U.S. alone, the Company
expects to significantly increase its efforts under the Partnership Program.
Commenting on the success of the Partnership Program, Edward Wright,
Chief Executive of CRH said, "I am delighted to report that our new physician
partners are reporting the same outstanding clinical outcomes that we
experienced in treating over 50,000 hemorrhoids in our own Centers in the
U.S." Wright further stated, "The Company expects to train in excess of 75
physicians in approximately 20 practices groups during the first quarter of
About CRH Medical Corporation:
CRH Medical Corporation specializes in the treatment of hemorrhoids
utilizing its proven treatment protocol and patented proprietary technology.
CRH's single use, disposable, hemorrhoid technology is safe and highly
effective in treating hemorrhoid grades I - IV. CRH Medical employs two
commercialization strategies: First, it operates Centers for Colorectal Health
facilities in the United States specializing in the treatment of hemorrhoids
and fissures, and colon cancer screening. In addition CRH distributes its
hemorrhoid banding technology, treatment protocols, operational and marketing
expertise as a complete, "turn key" package directly to its partner
physicians. The Company's goal is to establish the CRH hemorrhoid technology
as the standard for hemorrhoid treatment.
The information in this news release contains so-called "forward-looking"
statements. These include statements regarding CRH Medical expectations,
beliefs, intentions or strategies for the future, which may be indicated by
words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we
believe", "CRH Medical believes", "management believes" and similar language.
All forward-looking statements are based on CRH Medical current expectations
and are subject to risks and uncertainties and to assumptions made.
For further information call Dean Linden, Corporate Communications, CRH
Medical Corporation at 604.633.1440 or firstname.lastname@example.org. Additional
information may also be found by visiting the Company's website at
www.crhmedcorp.com or the SEDAR website at www.sedar.com.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information:
For further information: Investor Contact: Dean Linden, (604) 633-1440